{"id":7530,"date":"2025-12-20T01:35:30","date_gmt":"2025-12-19T16:35:30","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4528\/"},"modified":"2026-08-23T13:48:51","modified_gmt":"2026-08-23T04:48:51","slug":"company-4528","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4528\/","title":{"rendered":"ONO PHARMACEUTICAL CO"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4528","DATE":"2025-12-22","longName":"Ono Pharmaceutical Co., Ltd.","company_name_ja":"\u5c0f\u91ce\u85ac\u54c1\u5de5\u696d(\u682a)","fullTimeEmployees":4206,"address":"","phone":"","website":"https:\/\/www.ono-pharma.com","industry":"Drug Manufacturers - General","sector":"Healthcare","regularMarketPrice":2181,"financialCurrency":"","marketCap":1024868,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":148.41,"epsForward":0,"bookValue":0,"totalRevenue":515785000000,"OperatingIncome":92236000000,"operatingMargins":17.879999999999999,"NetIncome":69767000000,"profitMargins":13.529999999999999,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":8.1999999999999993,"recommendationMean":2.8333300000000001,"recommendationKey":"hold","targetMeanPrice":2500,"numberOfAnalystOpinions":12,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T04:57:46.758667\", \"ticker\": \"4528\", \"ticker_full\": \"4528.T\", \"company_name\": \"ONO PHARMACEUTICAL CO\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 0, \"buy\": 1, \"hold\": 8, \"sell\": 2, \"strong_sell\": 1, \"total_analysts\": 12, \"recommendation_key\": \"hold\", \"recommendation_mean\": 2.83333}, \"target_prices\": {\"has_data\": true, \"current\": 2384.0, \"high\": 3200.0, \"low\": 1900.0, \"mean\": 2500.0, \"median\": 2450.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": null, \"future_count\": 0, \"past_earnings\": [{\"date\": \"2026-07-30\", \"eps_estimate\": 35.66, \"eps_actual\": 51.4, \"surprise_pct\": 44.15}, {\"date\": \"2026-05-07\", \"eps_estimate\": 15.64, \"eps_actual\": 1.74, \"surprise_pct\": -88.88}, {\"date\": \"2026-02-01\", \"eps_estimate\": 48.74, \"eps_actual\": 61.42, \"surprise_pct\": 26.03}, {\"date\": \"2025-10-29\", \"eps_estimate\": 46.54, \"eps_actual\": 47.71, \"surprise_pct\": 2.52}, {\"date\": \"2025-07-31\", \"eps_estimate\": 48.36, \"eps_actual\": 37.62, \"surprise_pct\": -22.21}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 13.24, \"institution_pct\": 39.47, \"major_holders\": [{\"label\": \"\", \"value\": 13.24}, {\"label\": \"\", \"value\": 39.47}, {\"label\": \"\", \"value\": 45.49}, {\"label\": \"\", \"value\": 227.0}], \"institutional_holders\": [{\"holder\": \"Pacer Advisors, Inc.\", \"shares\": 215629, \"date_reported\": \"2025-09-30\", \"pct_held\": 0.04, \"pct_change\": 4.09, \"value\": 514059536}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 5727370, \"date_reported\": \"2026-04-30\", \"pct_held\": 1.15, \"pct_change\": -0.24, \"value\": 13654050080}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 3784306, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.76, \"pct_change\": 2.62, \"value\": 9021785504}, {\"holder\": \"Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.\", \"shares\": 3703700, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.74, \"pct_change\": 79.68, \"value\": 8829620800}, {\"holder\": \"iShares Trust-iShares Core MSCI EAFE ETF\", \"shares\": 2711500, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.54, \"pct_change\": 1.24, \"value\": 6464216000}, {\"holder\": \"BlackRock Funds-BlackRock Advantage International Fund\", \"shares\": 1884700, \"date_reported\": \"2026-05-31\", \"pct_held\": 0.38, \"pct_change\": 20.78, \"value\": 4493124800}, {\"holder\": \"Dimensional ETF Trust-Dimensional International Value ETF\", \"shares\": 1609690, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.32, \"pct_change\": 8.34, \"value\": 3837500960}, {\"holder\": \"iShares Trust-iShares MSCI EAFE Small-Cap ETF\", \"shares\": 1511000, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.3, \"pct_change\": 0.67, \"value\": 3602224000}, {\"holder\": \"WisdomTree Trust-WisdomTree Japan Hedged Equity Fund\", \"shares\": 1123300, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.23, \"pct_change\": 5.04, \"value\": 2677947200}, {\"holder\": \"Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund\", \"shares\": 971200, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.19, \"pct_change\": 35.32, \"value\": 2315340800}, {\"holder\": \"DEUTSCHE DWS INTERNATIONAL FUND, INC.-DWS CROCI International Fund\", \"shares\": 950900, \"date_reported\": \"2026-05-31\", \"pct_held\": 0.19, \"pct_change\": -6.47, \"value\": 2266945600}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":40,"get_dividend_history_year2":80,"get_dividend_history_year3":80,"get_dividend_history_year4":77,"get_dividend_history_year5":61,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T03:06:26.517209\", \"ticker\": \"4528\", \"ticker_full\": \"4528.T\", \"company_name\": \"ONO PHARMACEUTICAL CO\", \"company_info\": {\"name_en\": \"ONO PHARMACEUTICAL CO\", \"long_name\": \"Ono Pharmaceutical Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - General\", \"website\": \"https:\/\/www.ono-pharma.com\", \"employees\": 4206, \"country\": \"Japan\", \"city\": \"Osaka\", \"address\": \"8-2, Kyutaromachi 1-chome\", \"description\": \"Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 2447.7, \"deviation\": 0.01, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 2407.28, \"deviation\": 1.69, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 2381.5, \"deviation\": 2.79, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 2309.67, \"deviation\": 5.99, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 515785000000.0, \"revenue_fmt\": \"\u00a55158\u5104\", \"gross_profit\": 374069000000.0, \"gross_profit_fmt\": \"\u00a53741\u5104\", \"operating_income\": 92236000000.0, \"operating_income_fmt\": \"\u00a5922\u5104\", \"ebit\": 96193000000.0, \"ebit_fmt\": \"\u00a5962\u5104\", \"net_income\": 69767000000.0, \"net_income_fmt\": \"\u00a5698\u5104\", \"eps\": 148.41, \"operating_margin\": 17.88, \"total_assets\": 1106515000000.0, \"total_assets_fmt\": \"\u00a51.1T\", \"total_equity\": 850727000000.0, \"total_equity_fmt\": \"\u00a58507\u5104\", \"total_debt\": 120935000000.0, \"total_debt_fmt\": \"\u00a51209\u5104\", \"total_cash\": 237046000000.0, \"total_cash_fmt\": \"\u00a52370\u5104\", \"equity_ratio\": 76.88, \"de_ratio\": 0.14, \"current_ratio\": 2.86, \"operating_cf\": 136821000000.0, \"operating_cf_fmt\": \"\u00a51368\u5104\", \"investing_cf\": -39860000000.0, \"investing_cf_fmt\": \"-\u00a5399\u5104\", \"financing_cf\": -65493000000.0, \"financing_cf_fmt\": \"-\u00a5655\u5104\", \"free_cf\": 83551000000.0, \"free_cf_fmt\": \"\u00a5836\u5104\", \"net_margin\": 13.53, \"roe\": 8.2, \"roa\": 6.31}, {\"year\": 2025, \"revenue\": 486871000000.0, \"revenue_fmt\": \"\u00a54869\u5104\", \"gross_profit\": 338921000000.0, \"gross_profit_fmt\": \"\u00a53389\u5104\", \"operating_income\": 59748000000.0, \"operating_income_fmt\": \"\u00a5597\u5104\", \"ebit\": 64646000000.0, \"ebit_fmt\": \"\u00a5646\u5104\", \"net_income\": 50047000000.0, \"net_income_fmt\": \"\u00a5500\u5104\", \"eps\": 106.41, \"operating_margin\": 12.27, \"total_assets\": 1064046000000.0, \"total_assets_fmt\": \"\u00a51.1T\", \"total_equity\": 782451000000.0, \"total_equity_fmt\": \"\u00a57825\u5104\", \"total_debt\": 146678000000.0, \"total_debt_fmt\": \"\u00a51467\u5104\", \"total_cash\": 204567000000.0, \"total_cash_fmt\": \"\u00a52046\u5104\", \"equity_ratio\": 73.54, \"de_ratio\": 0.19, \"current_ratio\": 3.07, \"operating_cf\": 82459000000.0, \"operating_cf_fmt\": \"\u00a5825\u5104\", \"investing_cf\": -136785000000.0, \"investing_cf_fmt\": \"-\u00a51368\u5104\", \"financing_cf\": 94299000000.0, \"financing_cf_fmt\": \"\u00a5943\u5104\", \"free_cf\": 74469000000.0, \"free_cf_fmt\": \"\u00a5745\u5104\", \"net_margin\": 10.28, \"roe\": 6.4, \"roa\": 4.7}, {\"year\": 2024, \"revenue\": 502672000000.0, \"revenue_fmt\": \"\u00a55027\u5104\", \"gross_profit\": 375547000000.0, \"gross_profit_fmt\": \"\u00a53755\u5104\", \"operating_income\": 159936000000.0, \"operating_income_fmt\": \"\u00a51599\u5104\", \"ebit\": 163963000000.0, \"ebit_fmt\": \"\u00a51640\u5104\", \"net_income\": 127977000000.0, \"net_income_fmt\": \"\u00a51280\u5104\", \"eps\": 266.57, \"operating_margin\": 31.82, \"total_assets\": 913668000000.0, \"total_assets_fmt\": \"\u00a59137\u5104\", \"total_equity\": 792961000000.0, \"total_equity_fmt\": \"\u00a57930\u5104\", \"total_debt\": 8862000000.0, \"total_debt_fmt\": \"\u00a589\u5104\", \"total_cash\": 166141000000.0, \"total_cash_fmt\": \"\u00a51661\u5104\", \"equity_ratio\": 86.79, \"de_ratio\": 0.01, \"current_ratio\": 3.99, \"operating_cf\": 110660000000.0, \"operating_cf_fmt\": \"\u00a51107\u5104\", \"investing_cf\": 48077000000.0, \"investing_cf_fmt\": \"\u00a5481\u5104\", \"financing_cf\": -89848000000.0, \"financing_cf_fmt\": \"-\u00a5898\u5104\", \"free_cf\": 89831000000.0, \"free_cf_fmt\": \"\u00a5898\u5104\", \"net_margin\": 25.46, \"roe\": 16.14, \"roa\": 14.01}, {\"year\": 2023, \"revenue\": 447187000000.0, \"revenue_fmt\": \"\u00a54472\u5104\", \"gross_profit\": 337124000000.0, \"gross_profit_fmt\": \"\u00a53371\u5104\", \"operating_income\": 141963000000.0, \"operating_income_fmt\": \"\u00a51420\u5104\", \"ebit\": 144445000000.0, \"ebit_fmt\": \"\u00a51444\u5104\", \"net_income\": 112723000000.0, \"net_income_fmt\": \"\u00a51127\u5104\", \"eps\": 230.79, \"operating_margin\": 31.75, \"total_assets\": 882437000000.0, \"total_assets_fmt\": \"\u00a58824\u5104\", \"total_equity\": 741869000000.0, \"total_equity_fmt\": \"\u00a57419\u5104\", \"total_debt\": 9168000000.0, \"total_debt_fmt\": \"\u00a592\u5104\", \"total_cash\": 96135000000.0, \"total_cash_fmt\": \"\u00a5961\u5104\", \"equity_ratio\": 84.07, \"de_ratio\": 0.01, \"current_ratio\": 2.81, \"operating_cf\": 159610000000.0, \"operating_cf_fmt\": \"\u00a51596\u5104\", \"investing_cf\": -100259000000.0, \"investing_cf_fmt\": \"-\u00a51003\u5104\", \"financing_cf\": -32484000000.0, \"financing_cf_fmt\": \"-\u00a5325\u5104\", \"free_cf\": 145113000000.0, \"free_cf_fmt\": \"\u00a51451\u5104\", \"net_margin\": 25.21, \"roe\": 15.19, \"roa\": 12.77}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 61.0}, {\"year\": 2023, \"amount\": 77.0}, {\"year\": 2024, \"amount\": 80.0}, {\"year\": 2025, \"amount\": 80.0}, {\"year\": 2026, \"amount\": 40.0}], \"latest\": 40.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-7530","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ONO PHARMACEUTICAL CO - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4528\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/\",\"name\":\"ONO PHARMACEUTICAL CO - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2025-12-19T16:35:30+00:00\",\"dateModified\":\"2026-08-23T04:48:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4528\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ONO PHARMACEUTICAL CO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ONO PHARMACEUTICAL CO - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4528\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4528\/","url":"https:\/\/japanir.jp\/en\/company\/company-4528\/","name":"ONO PHARMACEUTICAL CO - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2025-12-19T16:35:30+00:00","dateModified":"2026-08-23T04:48:51+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4528\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4528\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4528\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"ONO PHARMACEUTICAL CO"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/7530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=7530"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=7530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}